Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Prion protein (PrP) systemic amyloidosis, previously known as chronic diarrhea with hereditary sensory and autonomic neuropathy is an extremely rare autosomal dominant disorder reported in three British families, a Japanese and an Italian family (about 16 cases in total). Onset is usually in the fourth decade of life and the course lasts about 20 years. Reported clinical manifestations include diarrhea, nausea, autonomic failure (areflexia, weakness), neurogenic bladder and urinary infections. The disorder is caused by truncation mutations of the prion protein gene PRNP (20p13) leading to deposition of prion protein amyloid.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for PrP systemic amyloidosis.
2 publications have been identified in PubMed for PrP systemic amyloidosis. Research spans Case Report / Case Series (50%) and Basic Science / Preclinical (50%).
Hafez SM (2026). [PMID: 41731624](https://pubmed.ncbi.nlm.nih.gov/41731624/). *BMC Pharmacol Toxicol*. [Basic Science / Preclinical]
Holm-Mercer L (2025). [PMID: 40611688](https://pubmed.ncbi.nlm.nih.gov/40611688/). *J Alzheimers Dis*. [Case Report / Case Series]
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 9:38 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about PrP systemic amyloidosis